Fenebrutinib

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameFenebrutinib
Drug Alias NameRO-7010939GDC-0853RG-7845G-0853
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsUrticariaLupus Erythematosus, SystemicMultiple Sclerosis, Chronic Progressive +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBosnia and HerzegovinaBulgaria +[44] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdGenentech IncPatheon Inc +[4] 
Inactive CompaniesN/A
Active IndicationsUrticariaLupus Erythematosus, SystemicMultiple Sclerosis, Chronic Progressive +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A